4.5 Article

Evolution of Targeted Prostate Biopsy by Adding Micro-Ultrasound to the Magnetic Resonance Imaging Pathway

期刊

EUROPEAN UROLOGY FOCUS
卷 7, 期 6, 页码 1292-1299

出版社

ELSEVIER
DOI: 10.1016/j.euf.2020.06.022

关键词

Prostate biopsy; Microultrasound; Target biopsy; Multiparametric magnetic resonance imaging; Prostate cancer

资金

  1. Exact Imaging Inc., Toronto, Canada

向作者/读者索取更多资源

The study evaluated micro-ultrasound of the prostate with real-time targeting of suspicious regions in patients suspected to have prostate cancer and found potential benefits in detecting cancer and clinically significant cancer. Micro-ultrasound appears to be a valuable addition and alternative to traditional ultrasound methods.
Background: Although multiparametric magnetic resonance imaging (mpMRI) revolutionized the implementation of prostate biopsies, a considerable amount of clinically significant prostate cancer (csPCa) is missed when performing mpMRI-targeted biopsies only. Microultrasound (micro-US) is a new modality that allows real-time targeting of suspicious regions. Objective: To evaluate micro-US of the prostate with real-time targeting of suspicious regions in patients suspected to have prostate cancer (PCa). Design, setting and participants: We examined 159 patients with prior mpMRI and suspicion of PCa with micro-US in the period from February to December 2018. Micro-US lesions were documented according to the prostate risk identification for micro-US (PRIMUS) protocol, and were blinded to the mpMRI results and targeted independently of the mpMRI lesions. Outcome measurements and statistical analysis: The main outcomes were cancer detection rate, additional detection of csPCa, and International Society of Urological Pathology (ISUP) grade group upgrading via micro-US. Results and limitation: PCa was found in 113/159 (71%) men, with 49% (78/159) having clinically significant cancer (csPCa; ISUP >= 2). Micro-US-targeted biopsies resulted in a higher ISUP grade group than the nontargeted biopsies in 26% (42/159), compared with both nontargeted and MRI-targeted biopsies in 16% (26/159). In 17% (27/159) of patients, targeted mpMRI-guided biopsy was negative with cancer identified in the micro-US-guided biopsy, of whom 20 had csPCa. The comparison with only MRI-positive patients is the main limitation of this analysis. Conclusion: Our data show an added benefit of micro-US in addition to mpMRI-targeted biopsies in a population of men at risk of PCa. A novel biopsy protocol with solely targeted biopsy with micro-US and mpMRI seems possible, replacing conventional ultrasound and omitting standard systematic biopsies. Patient summary: In this report, we looked at the performance of microultrasound in the setting of diagnosing prostate cancer. We found that microultrasound is a good addition to magnetic resonance imaging (MRI) of the prostate and presents an alternative for men who may not undergo MRI. (C) 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据